Cardiovascular Drugs Practice Questions

Q: A 34-year-old lady on antihypertensives presented with certain features. Which of the following drugs is likely responsible for this condition?

Minoxidil. ***Minoxidil*** - **Minoxidil** is a potent vasodilator that commonly causes **hypertrichosis** (excessive hair growth), particularly noticeable in women as unwanted facial and body hair. - This **cosmetic side effect** is dose-dependent and reversible upon discontinuation, making it a characteristic adverse effect of minoxidil therapy. *Enalapril* - **ACE inhibitors** like enalapril typically cause a **dry cough** (10-15% of patients) due to increased bradykinin levels. - Other common side effects include **hyperkalemia** and **angioedema**, but not hypertrichosis. *Trimetazidine* - This **anti-anginal agent** works by optimizing cardiac metabolism and rarely causes significant cosmetic side effects. - Main adverse effects include **gastrointestinal disturbances** and occasional **movement disorders**, not hair growth changes. *Methyldopa* - **Methyldopa** commonly causes **sedation**, **depression**, and **positive Coombs test** leading to hemolytic anemia. - Other notable side effects include **hepatotoxicity** and **drug-induced lupus**, but hypertrichosis is not associated with this medication.

Q: Which of the following drugs does NOT increase nitric oxide levels?

Fenoldopam. **Explanation:** The correct answer is **Fenoldopam** because its mechanism of action is entirely independent of the Nitric Oxide (NO) pathway. **1. Why Fenoldopam is the correct answer:** Fenoldopam is a selective **Dopamine $D_1$ receptor agonist**. It causes vasodilation by increasing intracellular cyclic AMP (cAMP) in vascular smooth muscle cells. It is unique because it causes rapid vasodilation while simultaneously increasing renal perfusion and promoting natriuresis (sodium excretion). It does not involve the release or stimulation of Nitric Oxide. **2. Why the other options are incorrect:** * **Glycerine trinitrate (GTN):** An organic nitrate that undergoes enzymatic conversion (via mitochondrial aldehyde dehydrogenase) to release **Nitric Oxide (NO)**, which activates guanylyl cyclase to increase cGMP. * **Sodium Nitroprusside (SNP):** A direct-acting vasodilator that non-enzymatically releases **Nitric Oxide** into the bloodstream. It acts on both arterioles and venules. * **Hydralazine:** Though its mechanism is complex, it is known to stimulate the release of **Nitric Oxide** from the vascular endothelium, leading to arteriolar vasodilation. **3. NEET-PG Clinical Pearls:** * **Fenoldopam** is the drug of choice for hypertensive emergencies in patients with **renal insufficiency** due to its renal-sparing effects. * **Sodium Nitroprusside** can lead to **Cyanide/Thiocyanate toxicity** with prolonged use; the antidote is Sodium Thiosulfate or Hydroxocobalamin. * **Nitrates** primarily cause venodilation (reducing preload), whereas **Hydralazine** primarily causes arteriolar dilation (reducing afterload). * **Tachyphylaxis** (tolerance) is a common issue with chronic Nitrate use, requiring a "nitrate-free interval."

Q: Which of the following antihypertensive medications can cause impotence?

Propranolol, Atenolol, Nifedipine. **Explanation:** The correct answer is **B (Propranolol, Atenolol, Nifedipine)**. Sexual dysfunction, specifically erectile dysfunction (impotence), is a well-documented side effect of several classes of antihypertensive drugs. **1. Why Option B is Correct:** * **Beta-Blockers (Propranolol, Atenolol):** These are the most common culprits. They cause impotence through multiple mechanisms: reducing central sympathetic outflow, causing peripheral vasoconstriction (via $\beta_2$ blockade), and potentially lowering testosterone levels. Non-selective blockers (Propranolol) generally have a higher incidence than cardioselective ones (Atenolol), but both are implicated. * **Calcium Channel Blockers (Nifedipine):** While less common than with beta-blockers or diuretics, dihydropyridine CCBs like Nifedipine have been associated with impotence in clinical practice and trials. **2. Analysis of Incorrect Options:** * **ACE Inhibitors (Options A & C):** These are considered "sexually neutral" or even beneficial. By blocking Angiotensin II (a vasoconstrictor), they may improve penile blood flow. Therefore, options containing ACE inhibitors are incorrect. * **Option D:** While both drugs cause impotence, this option is less comprehensive than Option B, which includes Atenolol—another major causative agent. **3. NEET-PG High-Yield Pearls:** * **Most Common Offenders:** Thiazide diuretics (e.g., Chlorthalidone) and Beta-blockers are the two classes most frequently associated with erectile dysfunction. * **The "Safe" Drugs:** ACE inhibitors, ARBs (especially **Losartan**, which may improve sexual function), and Nebivolol (a $\beta_1$ blocker that increases Nitric Oxide) are preferred in patients concerned about sexual side effects. * **Centrally Acting Drugs:** Clonidine and Methyldopa also have high rates of causing impotence due to their effect on the CNS.

Q: What is the primary route of administration for glyceryl trinitrate for acute angina relief?

Sublingual. Explanation: 1. Why Sublingual is Correct: Glyceryl Trinitrate (GTN) is the drug of choice for the immediate relief of an acute anginal attack. The sublingual route is preferred because the oral mucosa is highly vascular, allowing the drug to bypass the portal circulation [1]. This avoids the extensive first-pass metabolism (nearly 90%) that occurs in the liver [1]. It ensures a rapid onset of action (1–3 minutes), providing quick vasodilation of coronary arteries and peripheral veins, which reduces cardiac preload and myocardial oxygen demand [2]. 2. Why Other Options are Incorrect: * Oral: GTN has very low bioavailability when swallowed due to significant hepatic first-pass metabolism [1]. While sustained-release oral nitrates exist for prophylaxis, they are ineffective for acute relief. * Submucosal: While similar to sublingual, it is not the standard clinical practice for GTN administration. Sublingual placement (under the tongue) offers the most rapid absorption surface. * Rectal: Although this route bypasses some first-pass metabolism, it is clinically impractical, socially unacceptable for this indication, and has a much slower absorption rate compared to the sublingual route. 3. High-Yield Clinical Pearls for NEET-PG: * Storage: GTN is volatile and light-sensitive; it must be stored in dark-colored glass bottles with tight metal caps. * Patient Counseling: Patients should be told to sit down before taking the dose to avoid orthostatic hypotension and syncope. * Tolerance: To prevent "nitrate tolerance," a nitrate-free interval of 8–12 hours (usually at night) is required [2]. * Contraindication: Never co-administer with Sildenafil (PDE-5 inhibitors) as it can lead to life-threatening hypotension.

Q: Ivabradine is used in the treatment of which condition?

Angina. **Explanation:** **Ivabradine** is a unique cardiovascular drug that acts as a selective and specific inhibitor of the **cardiac pacemaker $I_f$ current** (the "funny" current) in the sinoatrial (SA) node. **1. Why Angina is Correct:** By inhibiting the $I_f$ current, Ivabradine slows the firing rate of the SA node, leading to a **dose-dependent reduction in heart rate**. Unlike beta-blockers, it reduces heart rate without affecting myocardial contractility (inotropy) or ventricular repolarization. In chronic stable angina, this reduction in heart rate decreases myocardial oxygen demand and increases diastolic perfusion time, effectively relieving ischemic symptoms. It is particularly useful in patients who have contraindications to beta-blockers (e.g., asthma). **2. Why Other Options are Incorrect:** * **Ventricular/Atrial Arrhythmias:** Ivabradine is not an anti-arrhythmic drug. It does not affect sodium, potassium, or calcium channels involved in tachyarrhythmias. In fact, it is ineffective in atrial fibrillation because the heart rate is not controlled by the SA node in that condition. * **Hypertension:** Ivabradine has no effect on peripheral vascular resistance or systemic blood pressure; therefore, it plays no role in treating hypertension. **3. High-Yield NEET-PG Pearls:** * **Mechanism:** Selective $I_f$ current inhibitor in the SA node. * **Clinical Use:** Chronic stable angina and Chronic Heart Failure (NYHA Class II-IV) with LVEF ≤ 35% in patients in sinus rhythm with a resting HR ≥ 70 bpm. * **Side Effects:** The most characteristic side effect is **luminous phenomena (phosphenes)**—enhanced brightness in limited areas of the visual field—caused by the inhibition of $I_h$ currents in the retina. * **Requirement:** The patient **must be in sinus rhythm** for the drug to be effective.

Q: What is the half-life of digoxin?

40 hours. **Explanation:** **Digoxin** is a cardiac glycoside used in the management of heart failure and atrial fibrillation. Its pharmacokinetic profile is a high-yield topic for NEET-PG. 1. **Why 40 hours is correct:** The average elimination half-life ($t_{1/2}$) of digoxin in a healthy individual with normal renal function is approximately **36 to 40 hours**. Because of this relatively long half-life, it takes about 5 to 7 days (4–5 half-lives) to reach a steady-state plasma concentration if a constant daily maintenance dose is started without a loading dose. 2. **Analysis of Incorrect Options:** * **24 hours (A):** This is too short for digoxin. However, it is closer to the half-life of *Digitoxin* in species with rapid metabolism, though in humans, Digitoxin lasts much longer (5–7 days). * **48 hours (C) & 60 hours (D):** While the half-life of digoxin can extend to 48–60 hours or more in patients with **renal impairment**, these are not the standard physiological values for a healthy adult. **High-Yield Clinical Pearls for NEET-PG:** * **Excretion:** Digoxin is primarily excreted **unchanged by the kidneys**. Therefore, the dose must be strictly reduced in patients with renal failure to prevent toxicity. * **Volume of Distribution:** It has a very high $V_d$ (approx. 6–7 L/kg) because it binds extensively to skeletal muscle (Na+/K+ ATPase). It is **not** removed by dialysis. * **Therapeutic Window:** It has a narrow therapeutic index (0.5–2 ng/mL). * **Toxicity Factors:** Hypokalemia, hypomagnesemia, and hypercalcemia predispose a patient to digoxin toxicity. The most common initial symptom of toxicity is anorexia/nausea, while the most characteristic arrhythmia is **Non-paroxysmal AV junctional tachycardia** and the most common is **PVCs**.

Q: Which beta-blocker possesses antioxidant properties?

Carvedilol. **Explanation:** **Carvedilol** is a unique, third-generation non-selective beta-blocker that also possesses alpha-1 ($\alpha_1$) blocking activity. Its **antioxidant properties** stem from its ability to scavenge free radicals and inhibit lipid peroxidation. This effect is attributed to its carbazole ring structure. By reducing oxidative stress and inhibiting the expression of adhesion molecules, carvedilol provides a "vasoprotective" effect, making it a cornerstone in the management of chronic heart failure (CHF) as it prevents remodeling. **Analysis of Incorrect Options:** * **A. Celiprolol:** A third-generation $\beta_1$-selective blocker with $\beta_2$-agonist and weak $\alpha_2$-blocking activity. It is known for its vasodilatory properties but lacks significant antioxidant effects. * **C. Betaxolol:** A cardioselective ($\beta_1$) blocker primarily used in glaucoma (topical) and hypertension. It does not possess antioxidant or vasodilatory properties. * **D. Propranolol:** A first-generation, non-selective beta-blocker. While it is highly lipid-soluble and has membrane-stabilizing activity, it does not have antioxidant capabilities. **High-Yield Clinical Pearls for NEET-PG:** * **Third-Generation Beta-Blockers:** Divided into Non-selective (Carvedilol, Labetalol) and $\beta_1$-selective (Nebivolol, Betaxolol, Celiprolol). * **Nebivolol:** Another third-generation blocker that causes vasodilation specifically via **Nitric Oxide (NO) release**. * **Heart Failure Trio:** The three beta-blockers proven to reduce mortality in CHF are **Carvedilol, Metoprolol succinate, and Bisoprolol.** * **Metabolic Profile:** Carvedilol is "metabolically neutral" or may improve insulin sensitivity, unlike older beta-blockers which can worsen glycemic control.

Q: Levosimendan is approved in which of the following conditions?

Heart failure. **Explanation:** **Levosimendan** is a novel cardiovascular drug classified as a **Calcium Sensitizer**. It is primarily used in the management of **acutely decompensated heart failure (ADHF)** where conventional therapies are insufficient. **Why Option A is Correct:** Levosimendan exerts its effect through a dual mechanism of action: 1. **Inotropic Effect:** It binds to cardiac **Troponin C** in a calcium-dependent manner. This increases the sensitivity of myofilaments to existing calcium, enhancing myocardial contractility without increasing intracellular calcium levels. Crucially, this improves stroke volume without significantly increasing myocardial oxygen demand or causing arrhythmias. 2. **Vasodilation:** It opens **ATP-sensitive potassium (K+ATP) channels** in vascular smooth muscle, leading to peripheral and coronary vasodilation (Inodilator). This reduces both preload and afterload. **Why Other Options are Incorrect:** * **B & C (Kidney/Liver Failure):** Levosimendan is not a treatment for organ failure in these systems. In fact, its active metabolite (OR-1896) is excreted renally, requiring cautious use or dose adjustment in severe renal impairment. * **D (Endocrine Crisis):** Conditions like thyroid storm or Addisonian crisis require specific hormonal stabilization (e.g., beta-blockers, steroids), not calcium sensitizers. **High-Yield Clinical Pearls for NEET-PG:** * **Unique Feature:** Unlike Dobutamine or Milrinone, Levosimendan does not increase intracellular calcium, making it less likely to cause calcium-overload-induced arrhythmias. * **Inodilator:** It belongs to the "Inodilator" class (Inotrope + Vasodilator). * **Indication:** Short-term treatment of severe ADHF when standard inotropes are inadequate. * **Side Effects:** Hypotension (due to vasodilation) and headache are the most common adverse effects.

Question 1

A 34-year-old lady on antihypertensives presented with certain features. Which of the following drugs is likely responsible for this condition?

Accepted Answer

Minoxidil

Answer

Enalapril

Answer

Trimetazidine

Answer

Methyldopa

Question 2

Which of the following drugs are known to cause fetal renal anomalies?

Accepted Answer

Enalapril

Answer

Frusemide

Answer

Angiotensin receptor blocker

Answer

Amlodipine

Question 3

Which of the following drugs does NOT increase nitric oxide levels?

Accepted Answer

Fenoldopam

Answer

Glycerine trinitrate

Answer

Hydralazine

Answer

Sodium Nitroprusside

Question 4

Which of the following antihypertensive medications can cause impotence?

Accepted Answer

Propranolol, Atenolol, Nifedipine

Answer

ACE inhibitors, Propranolol, Atenolol

Answer

ACE inhibitors, Atenolol

Answer

Propranolol, Nifedipine

Question 5

What is the primary route of administration for glyceryl trinitrate for acute angina relief?

Accepted Answer

Sublingual

Answer

Oral

Answer

Submucosal

Answer

Rectal

Question 6

Ivabradine is used in the treatment of which condition?

Accepted Answer

Angina

Answer

Ventricular arrhythmia

Answer

Atrial arrhythmia

Answer

Hypertension

Question 7

What is the half-life of digoxin?

Accepted Answer

40 hours

Answer

24 hours

Answer

48 hours

Answer

60 hours

Question 8

Monday disease is associated with exposure to which of the following substances?

Accepted Answer

Nitroglycerine

Answer

Verapamil

Answer

Benzodiazepines

Answer

Propranolol

Question 9

Which beta-blocker possesses antioxidant properties?

Accepted Answer

Carvedilol

Answer

Celiprolol

Answer

Betaxolol

Answer

Propranolol

Question 10

Levosimendan is approved in which of the following conditions?

Accepted Answer

Heart failure

Answer

Kidney failure

Answer

Liver failure

Answer

Endocrine crisis

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?